D. Boral Capital Reaffirms “Buy” Rating for ImmunityBio (NASDAQ:IBRX)

D. Boral Capital reiterated their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a research note published on Thursday,Benzinga reports. D. Boral Capital currently has a $30.00 price objective on the stock.

Several other analysts have also weighed in on IBRX. EF Hutton Acquisition Co. I raised ImmunityBio to a “strong-buy” rating in a research note on Wednesday, October 23rd. BTIG Research started coverage on shares of ImmunityBio in a report on Friday, January 10th. They issued a “buy” rating and a $6.00 target price for the company.

ImmunityBio Stock Performance

NASDAQ IBRX opened at $3.04 on Thursday. The business has a fifty day moving average price of $3.78 and a two-hundred day moving average price of $4.26. ImmunityBio has a fifty-two week low of $2.28 and a fifty-two week high of $10.53.

Institutional Investors Weigh In On ImmunityBio

Several hedge funds have recently modified their holdings of the company. State Street Corp increased its holdings in ImmunityBio by 10.1% in the 3rd quarter. State Street Corp now owns 8,654,460 shares of the company’s stock worth $32,195,000 after purchasing an additional 790,408 shares in the last quarter. Barclays PLC increased its stake in shares of ImmunityBio by 127.4% in the third quarter. Barclays PLC now owns 361,036 shares of the company’s stock valued at $1,344,000 after buying an additional 202,248 shares during the period. B. Riley Wealth Advisors Inc. bought a new position in ImmunityBio in the 2nd quarter valued at approximately $515,000. GSA Capital Partners LLP boosted its position in ImmunityBio by 290.3% during the 3rd quarter. GSA Capital Partners LLP now owns 107,985 shares of the company’s stock worth $402,000 after buying an additional 80,318 shares during the period. Finally, Private Advisor Group LLC grew its holdings in ImmunityBio by 727.7% during the 2nd quarter. Private Advisor Group LLC now owns 86,907 shares of the company’s stock worth $549,000 after acquiring an additional 76,407 shares during the last quarter. Institutional investors and hedge funds own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.